Aug. 25 at 8:45 PM
Jazz Pharmaceuticals said the FDA approved two first-line combination regimens containing Ziihera (zanidatamab-hrii) for adults with unresectable or metastatic HER2-positive gastroesophageal adenocarcinoma. The approval includes a triple regimen combining Ziihera with Tevimbra (tislelizumab-jsgr) and chemotherapy, and a double regimen combining Ziihera with chemotherapy, targeting different HER2 expression profiles.
The FDA decision sent Jazz shares to a record intraday high of
$266.38. Investor confidence had already strengthened after a strong Q2 2026 report, with revenue reaching
$1.21 billion, well above consensus. Wall Street price targets ranged from
$264 to
$310.
BeOne Medicines and Zymeworks, which originated zanidatamab, also gained following the approval. Overall, the FDA decision and Jazz’s solid financial performance reinforced optimism around its oncology growth prospects.
$JAZZ $ONC $ZYME